EFTR - צמיחת מכירות ב-12 חודשים נגררים eEFFECTOR

eFFECTOR Therapeutics (EFTR) management has decided to shut down the business following the failure of key tests. The year-over-year revenue change over the trailing twelve months (TTM) clearly demonstrates this decline. The development of targeted protein blockers and risks of equipment supply chain disruptions influenced the outcome, where the value of -77.00 reflects this status.
eFFECTOR Therapeutics - פילוחים אנליטיים ומדדי מפתח (EFTR)

Fundamental asset screening requires the rapid identification of revenue trends, which is achieved by calculating the rolling 12-month change in sales. Analyzing comparable year-over-year sales growth over 12 months allows for an assessment of the commercial resilience of eFFECTOR Therapeutics (EFTR) during a period of capital austerity and a management-led revision of R&D strategy following the reduction of several clinical trials.